All In Biotech

Drug Trial Radar · NCT02269917

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects

Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,149

Actual

Start

Mar 2015

Primary completion

Feb 2017

Study completion Oct 2020

Sponsor

Lead sponsor
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid \[HIV-1 RNA\] concentrations less than \[\<\] 50 copies per milliliter \[copies/mL\]) HIV-1 infected participants.

Conditions

  • Human Immunodeficiency Virus Type 1

Interventions

  • D/C/F/TAFDrug

    Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.

  • Boosted Protease Inhibitor (bPI)Drug

    Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.

  • FTC/TDFDrug

    Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48Time frame: Through Week 48

Locations

79 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Bakersfield, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Ft. Pierce, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Berkley, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Hillsborough, New Jersey

  • Site not named

    Newark, New Jersey

  • Site not named

    Somers Point, New Jersey

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Providence, Rhode Island

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Longview, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Antwerp, Belgium

  • Site not named

    Brussels, Belgium

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.